NCT03943875View on ClinicalTrials.gov

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

757

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

January 13, 2025

Study Completion Date

March 1, 2026

Conditions
ImmunizationEfficacyHuman Papilloma Virus
Interventions
BIOLOGICAL

9-valent HPV vaccine, 2 dose efficacy

Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.

BIOLOGICAL

9-valent HPV vaccine, 3 doses standard timing

Will be comparison group for 2 dose efficacy group.

Trial Locations (1)

77555

University of Texas Medical Branch, Galveston

All Listed Sponsors
collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

The University of Texas Medical Branch, Galveston

OTHER